-
公开(公告)号：US08193318B2
公开(公告)日：2012-06-05
申请号：US12186058
申请日：2008-08-05
CPC分类号： C07K16/283 , A61K2039/505 , C07K16/2896 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/732
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof for the treatment, prevention, management, or amelioration of a disease or disorder. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
摘要翻译： 本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA特异性结合FcγRIIB的抗体或其片段。 本发明还包括抗FcγRIIB抗体或其抗原结合片段用于治疗，预防，治疗或改善疾病或病症的用途。 本发明还提供了通过施用本发明的抗体来增强治疗性抗体的效应子功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过用疫苗组合物施用本发明的抗体来增强疫苗组合物的功效的方法。 本发明还提供了通过施用本发明的抗原 - 抗体复合物和抗体来破坏对抗原的耐受性的方法。
-
32.发明授权Identification and engineering of antibodies with variant Fc regions and methods of using same 有权具有变体Fc区的抗体的鉴定和工程及其使用方法公开(公告)号：US08192737B2
公开(公告)日：2012-06-05
申请号：US12022772
申请日：2008-01-30
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K14/70535 , C07K14/36 , C07K14/405 , C07K16/005 , C07K16/283 , C07K16/2887 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/70 , G01N33/6857 , G01N2333/70535
摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
摘要翻译： 本发明涉及包括变体Fc区的分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区 相对于包含野生型Fc区的可比分子，以更高的亲和力结合FcγRIIIA和/或FcγRIIA。 本发明的分子特别可用于预防，治疗或改善与疾病，病症或感染相关的一种或多种症状。 本发明的分子特别可用于治疗或预防期望由FcγR介导的效应细胞功能增强的功效（例如ADCC）的疾病或病症，例如癌症，感染性疾病和增强治疗功效 的治疗性抗体，其作用由ADCC介导。
-
公开(公告)号：US08137916B2
公开(公告)日：2012-03-20
申请号：US12912421
申请日：2010-10-26
申请人： Zsuzsanna Nagy
发明人： Zsuzsanna Nagy
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention relates to genetic screens for susceptibility to Alzheimer's disease. In particular, the invention provides genetic screens based on genotyping of the p21E2c31 C/A polymorphism and/or the p21E3+20 C/T polymorphism in the p21cip 1 gene.
摘要翻译： 本发明涉及对阿尔茨海默病易感性的遗传筛选。 特别地，本发明提供了基于p21E2c31 C / A多态性和/或p21C3 + 20C / T多态性在p21cip1基因中的基因分型的遗传筛选。
-
公开(公告)号：US08137668B2
公开(公告)日：2012-03-20
申请号：US11482660
申请日：2006-07-06
申请人： Ronghao Li
发明人： Ronghao Li
CPC分类号： C07K16/18 , A61K47/6843 , C07K16/00 , C07K2317/21
摘要： The present invention provides a method for generating human monoclonal antibodies, especially those that are specific for surface antigens representative of a particular cell type. The present invention also includes populations of monoclonal antibodies produced by the invention methods, populations of polynucleotides comprising sequences encoding the immunoglobulins or fragments thereof, which are capable of binding to antigens representative of a cell type of interest.
摘要翻译： 本发明提供了产生人单克隆抗体的方法，特别是代表特定细胞类型的表面抗原特异性的那些。 本发明还包括通过本发明方法产生的单克隆抗体群，包含能够结合代表感兴趣的细胞类型的抗原的编码免疫球蛋白或其片段的多核苷酸群体。
-
35.发明授权Identification and engineering of antibodies with variant Fc regions and methods of using same 有权具有变体Fc区的抗体的鉴定和工程及其使用方法公开(公告)号：US07960512B2
公开(公告)日：2011-06-14
申请号：US10902588
申请日：2004-07-28
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/00 , C07K16/005 , C07K2317/52 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
摘要翻译： 本发明涉及包括变体Fc区的分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区 相对于包含野生型Fc区的可比分子，以更高的亲和力结合FcγRIIIA和/或FcγRIIA。 本发明的分子特别可用于预防，治疗或改善与疾病，病症或感染相关的一种或多种症状。 本发明的分子特别可用于治疗或预防需要由FcγR介导的效应细胞功能增强的功效（例如ADCC）的疾病或病症，例如癌症，感染性疾病和增强治疗功效 的治疗性抗体，其作用由ADCC介导。
-
-
-
-
搜索结果
35 条记录 (耗时 0.046 秒)
